Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Intuitive Surgical (ISRG): The Robot is Well-Oiled NOW, But Is It Already Priced for Perfection? -What’s the Impact & its 5 Biggest Catalysts Driving the Future Outlook !
Intuitive Surgical closed 2024 with strong momentum, driven by 17% YoY procedure volume growth and a 15% installed base expansion. Revenue reached $8.4B (+17% YoY), with da Vinci 5 placements exceeding expectations. Q4 revenue of $2.41B and adjusted EPS of $2.21 beat estimates, reflecting solid top-line performance and operational leverage. U.S. general surgery and international markets drove growth, while capital deployments remained resilient. 2025 procedure growth is projected at 13-16%, with gross margin expected at 67-68% due to various pressures. Despite near-term headwinds, long-term margin expansion remains possible. Competitive entrants are emerging, but Intuitive's ecosystem, innovation, and recurring revenue model create a strong moat. While the long-term outlook is positive, the current valuation at a 25x P/S multiple reflects high expectations. Given the increasing competition and potential margin pressures, can Intuitive Surgical continue to innovate and expand its market share enough to justify its premium valuation, or has the market already priced in all future growth potential?
